Journal article · 2026 · Open access

Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF )

Hossam Sharaf, Moheb Wadie, Noha O. Mansour, Mohamed E. E. Shams

Clinical Pharmacology & Therapeutics · Published 3 November 2026 · DOI 10.1002/cpt.70540

Open PDFView at the publisherCite this paper

In brief

“Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF )” is a 2026 journal article by Hossam Sharaf and 3 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 0 citations as of 17 November 2026. It is open access: the full text is free to read at Clinical Pharmacology & Therapeutics.

Citations
0
References
44
Authors
4

Abstract

Early adjunctive therapies may improve decongestion and symptoms in acute heart failure. This trial compared dapagliflozin with acetazolamide when initiated early, focusing on dyspnea relief as the primary outcome and decongestive, diuretic, natriuretic, and safety outcomes. In this randomized, active-controlled trial, 108 adults hospitalized with acute heart failure, dyspnea, and objective evidence of congestion requiring intravenous loop diuretics were randomized to receive dapagliflozin 10 mg (N = 55) or acetazolamide 500 mg (N = 53) once daily for 3 days alongside standard care. The primary endpoint was the between-group difference in 72-hour dyspnea visual analog scale area under the curve. Secondary endpoints included successful decongestion within 3 days, diuretic and natriuretic responses, the relative change in N-terminal pro-B-type natriuretic peptide levels from baseline to day 3, and safety. Acetazolamide produced a significantly lower 72-hour dyspnea area under the curve than dapagliflozin (2647.9 ± 1213.8 vs. 2988.7 ± 1196.7 mm × hour; P = 0.048). It increased cumulative urine output over 72 hours (12,200 vs. 10,000 mL; P = 0.019) and total natriuresis over 48 hours (824.7 vs. 547.9 mmol; P = 0.001). Dapagliflozin achieved a larger reduction in N-terminal pro-B-type natriuretic peptide at 72 hours (-34.2% vs. -25.0%; P = 0.003). Safety events were infrequent and similar. In conclusion, acetazolamide provided greater dyspnea relief, diuresis, and natriuresis, whereas dapagliflozin produced a larger short-term reduction in N-terminal pro-B-type natriuretic peptide. Further studies are needed to validate these findings. Trial registration: https://clinicaltrials.gov/study/NCT06783166.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Sharaf, H., Wadie, M., Mansour, N. O., & Shams, M. E. E. (2026). Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF ). Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70540

MLA 9

Sharaf, Hossam, et al. “Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF ).” Clinical Pharmacology & Therapeutics, 2026. https://doi.org/10.1002/cpt.70540.

Chicago

Sharaf, Hossam, Moheb Wadie, Noha O. Mansour, and Mohamed E. E. Shams. 2026. “Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF ).” Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70540.

Harvard

Sharaf, H. et al. (2026) ‘Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF )’, Clinical Pharmacology & Therapeutics. doi:10.1002/cpt.70540.

IEEE

H. Sharaf, M. Wadie, N. O. Mansour, and M. E. E. Shams, “Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF ),” Clinical Pharmacology & Therapeutics, 2026, doi: 10.1002/cpt.70540.

BibTeX

@article{sharaf2026dapagliflozin,
  title     = {{Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF )}},
  author    = {Sharaf, Hossam and Wadie, Moheb and Mansour, Noha O. and Shams, Mohamed E. E.},
  journal   = {Clinical Pharmacology \& Therapeutics},
  year      = {2026},
  doi       = {10.1002/cpt.70540},
  url       = {https://doi.org/10.1002/cpt.70540}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management

  • dapagliflozin
  • acetazolamide
  • acute heart failure
  • dyspnea
  • decongestion
  • diuresis
  • sodium excretion
  • N-terminal pro-brain natriuretic peptide

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Sharaf, H., Wadie, M., Mansour, N. O., & Shams, M. E. E. (2026). Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF ). Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70540

How many times has this paper been cited?

0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the PDF from this page.

Who wrote this paper?

Hossam Sharaf, Moheb Wadie, Noha O. Mansour, Mohamed E. E. Shams.

What is the DOI of this paper?

10.1002/cpt.70540, permanently at https://doi.org/10.1002/cpt.70540. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.